In Brief: Hoechst Marion Roussel's Anzemet
Hoechst Marion Roussel's Anzemet: NDAs have been submitted for dolasetron mesylate for the prevention of nausea and vomiting in patients undergoing chemotherapy and surgery, company announces April 15. Anzemet is a 5-HT3 receptor antagonist in oral once-a-day and I.V. dosages...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth